Nikom Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 2.10 M
- Company Age 21 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 25.76 Cr
- Revenue Growth -28.65%
- Profit Growth 86.98%
- Ebitda -57.42%
- Net Worth 9.01%
- Total Assets -10.11%
About Nikom Pharmaceutical
Nikom Pharmaceutical Private Limited (NPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 04 July 2003 and has a history of 21 years and seven months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 2.10 M.
The company currently has active open charges totaling ₹25.76 Cr.
Jayant Mirani, Akella Subrahmanyam, and Anagha Pathak serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230MH2003PTC141173
-
Company No.
141173
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
04 Jul 2003
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Nikom Pharmaceutical?
Board Members (3)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Jayant Mirani | Additional Director | 08-Nov-2021 | Current |
Akella Subrahmanyam | Director | 25-Jun-2015 | Current |
Anagha Pathak | Additional Director | 17-Jul-2021 | Current |
Financial Performance of Nikom Pharmaceutical.
Nikom Pharmaceutical Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 28.65% decrease. The company also saw a substantial improvement in profitability, with a 86.98% increase in profit. The company's net worth moved up by a moderate rise of 9.01%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Nikom Pharmaceutical?
In 2020, Nikom Pharmaceutical had a public holding of 0.05%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹25.76 Cr
₹0
Charges Breakdown by Lending Institutions
- Others : 25.76 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
29 Aug 2022 | Others | ₹3.50 Cr | Open |
18 Jun 2018 | Others | ₹2.20 M | Open |
19 Mar 2012 | Others | ₹22.04 Cr | Open |
How Many Employees Work at Nikom Pharmaceutical?
Unlock and access historical data on people associated with Nikom Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nikom Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nikom Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.